This finding is in agreement with a recent publication by Kiessling et al, who showed that the mTORC1/2 inhibitor, everolimus, alone was sufficient to inhibit cell growth in NRAS mutant neuroblastoma cell lines (Kiessling et al., 2016). Here, NRAS is linked to neuroblastoma.